The
global Advanced
Therapy Medicinal Products CDMO Market size is expected to reach USD 18.8
billion by 2030, according to a new report by Grand View Research, Inc. The
market is expected to register a CAGR of 18.92% from 2024 to 2030, owing to
rising clinical trials for advanced therapy medicinal products and
the increasing awareness among researchers about the benefits of advanced
therapies, driving the advanced therapy medicinal products (ATMP) CDMO market
growth. Tissue engineering has greatly benefited in recent years from
technological development. The damaged tissues and organ function are replaced
or restored using this technique. Similarly, gene and cell therapy are
attracting a lot of patients for the treatment of rare diseases, whose
incidence is rising globally.
With
rising demand for robust disease treatment therapies, key players have focused
their efforts to ramp up research and development for effective gene therapies
that target the cause of disorder at a genomic level. According to ASGCT, the
number of cell and gene therapies in the U.S. pipeline programs (phase I-III
trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA
delivers constant support for innovations in the gene therapy field via a
number of policies with regard to product manufacturing. In January 2020, the
agency released six final guidelines on the manufacturing and clinical
development of safe & efficient gene therapy products.
Moreover,
awareness about ATMP treatment options is being driven by initiatives aimed at
informing the public about the benefits of these products, which, in turn, is
leading to increased adoption of advanced therapies and fueling market growth
for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell
and Gene Medicine prioritizes activities for increasing public awareness
through educational programs, underlining the clinical & societal benefits
of regenerative medicine.
Increasing
clinical trial activity along with new product launches generates growth
opportunities for the market. As of 2022, there are 1451 ATMPs in preclinical
stages and 535 are being studied in Phase 1 to 3 studies. Since August 2020,
EMA has approved six of these additional ATMPs, and five more will be approved
by 2023. In the UK, there were approximately 168 advanced therapy medicinal
product trials underway in 2021, up from the 154 studies reported the year
before, which is a 9% increase. 2021 saw a 32% increase in phase 1 trials,
indicating a significant shift from experimental medicines to first-in-human
studies.
On
the other hand, key players are undertaking various strategic initiatives to
introduce novel products, which is expected to propel market growth. For
instance, in March 2021, CureVac N.V. signed a partnership agreement with
Celonic Group, engaged in the manufacture of CVnCoV, CureVac’s mRNA-based
COVID-19 vaccine candidate. CureVac's COVID-19 vaccine candidate is
manufactured at Celonic's commercial manufacturing unit for ATMPs and biologics
in Heidelberg, Germany. Under the terms of the commercial supply agreement, the
Celonic facility could produce over 100 million doses of CVnCoV.
List of Key Players of Advanced Therapy Medicinal
Products CDMO Market
- Celonic
- Bio Elpida
- CGT Catapult
- Rentschler
Biopharma SE
- AGC
Biologics
- Catalent
- Lonza
- WuXi
Advanced Therapies
- BlueReg
- Minaris
Regenerative Medicine
- Patheon
Related Press
Release@ Advanced
Therapy Medicinal Products CDMO Market Report
Advanced Therapy Medicinal Products CDMO Market Report
Highlights
- The gene
therapy segment held the largest share of over 49.2% in 2023.
Increase in financial support and rise in number of clinical trials for
gene therapies are driving demand for the gene therapy segment.
- The cell
therapy segment is expected to show lucrative growth over the
forecast period. The field of cellular therapeutics is constantly
advancing with inclusion of new cell types, which, in turn, provides ample
opportunities for companies to enhance their market positions.
- The oncology
segment accounted for the largest revenue share in 2023. The segment’s
dominance is attributed to disease burden, strategic initiatives
undertaken by key players, and availability of advanced therapies used for
treating various cancer indications.
- The phase I
segment dominated the market in 2023 due to growing R&D activities and
increasing number of human trials for advanced therapies.
- North
America dominated the overall market share of 49.0% in 2023. This can be
attributed to increasing outsourcing activities and rising awareness about
advanced therapy.
- The Asia
Pacific region is expected to grow at the fastest CAGR over the forecast
period due to the increasing demand for novel ATMPs and rising R&D
activities to develop novel therapies.
Advanced Therapy Medicinal
Products CDMO Market Report Scope
|
Report Attribute |
Details |
|
Market
size value in 2024 |
USD 6.6
billion |
|
Revenue
forecast in 2030 |
USD 18.8
billion |
|
Growth
rate |
CAGR of
18.92% from 2024 to 2030 |
|
Base year
for estimation |
2023 |
|
Historical data |
2018 - 2022 |
|
Forecast period |
2024 - 2030 |
Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/452243/rfc
Advanced Therapy Medicinal Products CDMO Market
Segmentation
Grand
View Research has segmented the global advanced therapy medicinal products CDMO
market report based on product, phase, indication, and region:
Advanced Therapy Medicinal Products CDMO Product Outlook
(Revenue, USD Million, 2018 - 2030)
- Gene Therapy
- Cell Therapy
- Tissue
Engineered
- Others
Advanced Therapy Medicinal Products CDMO Phase Outlook
(Revenue, USD Million, 2018 - 2030)
- Phase I
- Phase II
- Phase III
- Phase IV
Advanced Therapy Medicinal Products CDMO Indication
Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Cardiology
- Central
nervous system
- Musculoskeletal
- Infectious
disease
- Dermatology
- Endocrine,
metabolic, genetic
- Immunology
& inflammation
- Ophthalmology
- Hematology
- Gastroenterology
- Others
Advanced Therapy Medicinal Products CDMO Regional Outlook
(Revenue, USD Million, 2018 - 2030)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- Thailand
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle East
& Africa
- South
Africa
- Saudi
Arabia
- UAE
- Kuwait
No comments:
Post a Comment